Clofarabine, Cytarabine Combo Significantly Prolongs Survival in AML Patients

Share this content:
(ChemotherapyAdvisor) – Clofarabine plus cytarabine (Clo+Ara-C) significantly prolongs event-free survival (EFS), according to an international team of researchers. This conclusion is based on a study entitled “Clofarabine plus Cytarabine Compared with Cytarabine Alone in Older Patients with Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial,” which was published in the July 10 issue of the Journal of Clinical Oncology.

In this study, the investigators aimed to compare the effectiveness of administering clofarabine plus cytarabine (Clo+Ara-C arm) with cytarabine (Ara-C arm) to treat patients ≥55 years old who been previously diagnosed with refractory or relapsed acute myelogenous leukemia (AML). To meet this aim, patients (N=82) were randomized to receive clofarabine (Clo) 40mg/m2 or a placebo followed by Ara-C 1g/m2 for 5 consecutive days, until they reached pre-selected end points [primary: overall survival (OS); secondary: event-free survival (EFS), 4-month EFS, overall remission rate (ORR), disease-free survival (DFS), duration of remission (DOR), and safety.]

The investigators reported the following results. The median OS was 6.6 months in the Clo+Ara-C arm and 6.3 months in the Ara-C arm (hazard ratio [HR], 1.00; 95% CI, 0.78 to 1.28; P=1.00). The ORR was 46.9% in the Clo+Ara-C arm (35.2% CR) vs 22.9% in the Ara-C arm (17.8% CR; P<.01). EFS (HR: 0.63; 95% CI, 0.49 to 0.80; P<.01) and 4-month EFS (37.7% vs 16.6%; P<.01) favored the Clo+Ara-C arm compared with Ara-C arm, respectively. DFS and DOR were similar in both arms. In the Clo+Ara-C and Ara-C arms, the most common grade 3/4 toxicities were febrile neutropenia (47% vs 35%, respectively), hypokalemia (18% vs 11%, respectively), thrombocytopenia (16% vs 17%, respectively), pneumonia (14% vs 10%, respectively), anemia (13% vs 0%, respectively), neutropenia (11% vs 9%, respectively), increased AST (11% vs 2%, respectively), and increased ALT (10% vs 3%, respectively).

The investigators concluded: “Although the primary end point of OS did not differ between arms, Clo+Ara-C significantly improved response rates and EFS.”


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs